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Chronic wounds are the result of excessive amounts of tissue destructive proteases such as human neutrophil
elastase (HNE). The high levels of this enzyme found on those types of wounds inactivate the endogenous
inhibitor barrier thus, the search for new HNE inhibitors is required.
This work presents two new HNE inhibitor peptides, which were synthesized based on the reactive-site loop
of the Bowman–Birk inhibitor protein. The results obtained indicated that these new peptides are competitive
inhibitors for HNE and, the inhibitory activity can be modulated by modiﬁcations introduced at the N- and C-
terminal of the peptides. Furthermore, these peptides were also able to inhibit elastase from a human wound
exudate while showing no cytotoxicity against human skin ﬁbroblasts in vitro, greatly supporting their
potential application in chronic wound treatment.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
Human neutrophil elastase (HNE) (EC 3.4.21.37) is a serine
protease of the chymotrypsin family that is stored in the primary
(azurophil) granules of polymorphonuclear neutrophils (PMNs) and
is released by inﬂammatory stimuli. Under normal conditions the
activity of HNE is regulated by endogenous inhibitors like secretory
leukocyte protease inhibitor and elaﬁn. The continuous activation of
inﬂammatory cells is followed by the release of large quantities of
HNE which inactivate the inhibitor defense. Excessive and uncon-
trolled HNE activity has been implicated in mediating tissue damage
associated with chronic wounds and other major chronic inﬂamma-
tory diseases including rheumatoid arthritis (Ekerot and Ohlsson,
1984) and chronic obstructive pulmonary disease (Shapiro, 2002). In
the area of wound healing, the presence of high levels of HNE is
associated with the degradation of important growth factors (Yager et
al., 1997) and major proteins of the extracellular matrix like
ﬁbronectin (Grinnell and Zhu, 1994) which are vital for the normal
wound healing process. Due to its involvement in such pathological
processes, there has been considerable interest in the design of HNE
inhibitors that may restore the normal levels of this enzyme in the
above diseases. Apart from natural or engineered inhibitor proteins of
highmolecular mass, there has been an increasing interest in studying
both peptide-based and non-peptide small inhibitor compounds
(Edwards and Bernstein, 1994).
The Bowman–Birk inhibitors are bi-headed serine proteinase
inhibitors found in plants of the Fabaceae family (Norioka and
Ikenaka, 1983). These proteins have a low molecular weight (6–
9 kDa) and are characterized by the presence of seven disulphide
bridges which allow the formation of a symmetrical structure
comprising two independent heads located at opposite sides of the
molecule (see Fig. 1). Each head is made of a tricyclic domain in which
the functional reactive site loop is located. Loop I typically inhibits
trypsin and loop I' inhibits chymotrypsin (Chen et al., 1992; Lin et al.,
1993; Voss et al., 1996; Werner and Wemmer, 1992). The interaction
of Bowman–Birk inhibitor with serine proteases occurs via a well-
deﬁned disulﬁde linked short beta-sheet region which generates a
non-covalent complex that renders the serine protease inactive
(McBride and Leatherbarrow, 2001). The conformation of the reactive
site loop is complementary to the active site of the protease inhibited
and allows Bowman–Birk inhibitor to tightly bind to the protease
(Chen et al., 1992). Bowman–Birk inhibitor-derived synthetic pep-
tides have previously been demonstrated to retain the inhibitory
activity of the complete protein (McBride et al., 2002).
The present work is based on the ability to retain inhibitory
activity of short peptide sequences that reproduce the reactive site-
loop of Bowman–Birk inhibitor protein (Mcbride et al., 1999; Nishino
et al., 1977; Odani and Ikenaka, 1973; Terada et al., 1978). The
synthetic peptide sequences were tested as inhibitors of HNE and
porcine pancreatic elastase (PPE) to determine the speciﬁcity of the
peptides. Furthermore, the inhibitory activity of these peptides was
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also tested using chronic wound exudate, in order to evaluate their
ability to be used as a part of a wound management strategy.
2. Materials and methods
The Porcine Pancreatic Elastase (PPE), Human Neutrophil Elastase
(HNE) and Elastatinal were purchase from Sigma, Spain. The peptides
2 (MGWCTASVPPQCYG, 1499.75 g/mol) and 3 (MGWCTASVPPQCYG
(GA)7, 2339.62 g/mol) were synthesized by JPT Peptide Technologies
GmbH (Germany). The BJ5ta cell line (telomerase-immortalized
human normal skin ﬁbroblasts) was purchased from the European
Collection of Cell Cultures (ECACC) and cultured according to ATCC
recommendations. All other reagents, including those used in cell
culture, were analytical grade and purchased from Sigma, Spain.
2.1. Collection of wound exudate
Wound exudate was collected from pressure wounds using a
vacuum assisted closure system by the Medisch Spectrum in Twente.
Wound ﬂuid samples were weighed and 100 μl of phosphate buffer
pH 7.0 were then added to 10 mg of wound ﬂuid. Samples were
incubated at room temperature for 1 h and then centrifuged at 1000 g
for 20 min to remove cells and tissue-material. After centrifugation
the wound exudate was sterilized using Oxy Fil Centrifugal Filter
(0.2 μm membrane pore diameter). The samples were then ready for
storage at −20 °C until further use. The total protein content in the
wound exudate was determined by the Lowry method (Lowry et al.,
1951).
2.2. Determination of activity loss over time
The half-life times for HNE, exudate and PPE were determined
following the incubation with different concentrations of inhib-
itor peptides (20–80 μM) at 25 °C. The concentrations of HNE,
exudate and PPE were 20 μg/ml, 2.4 μg/ml and 175 μg/ml
respectively. At determined time points, aliquots were taken
and the activity was determined against the synthetic substrates,
5 mM of N-Methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide for
HNE and exudate. A stock solution of this substrate of 20 mM
was prepared in DMSO (dimethyl sulfoxide). To prepare the 5 mM
solution, the required amount of the stock solution was added to
0.1 M HEPES buffer, 0.5 M NaCl, pH 7.5. The substrate used for PPE
was N-Succinyl-Ala-Ala-Ala-p-nitroanilide, 4.4 mM prepared in
0.1 M Tris–HCl buffer, pH 8.0. The absorbance was monitored for
5 min at 410 nm using a Heλios γ ThermoSpectronic spectropho-
tometer. Control assays were performed in the same conditions but
without inhibitor. Measurements were recorded in triplicate and the
results were expressed as mean value±S.D. (standard deviation).
2.3. Inhibition kinetics
The inhibition kinetics of the peptides was determined by
competitive binding studies (Domingo et al., 1995; Gariani et al.,
1999). Brieﬂy, 15 μl of proteases (HNE (20 μg/ml)), exudate (2.4 μg/ml)
and PPE (175 μg/ml) were incubated with 15 μl of peptide inhibitors
(20–80 μM) for 30 min at 25 °C. The ﬁnal volume of each sample was
adjusted to 300 μl with 0.1 M HEPES buffer, 0.5 M NaCl, pH 7.5 (HNE
and exudate) and 0.1 M Tris–HCl buffer, pH 8.0 (PPE). The reaction was
initiated with the addition of an adequate volume of substrate to obtain
a substrate concentration range of 100–3000 μM. The substrate for HNE
and exudate is N-Methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide
5 mM and for PPE is N-Succinyl-Ala-Ala-Ala-p-nitroanilide 4.4 mM
prepared in the respective buffer solutions. The residual activity was
determined by the increase in the optical density at 410 nm over
10 min using a microplate reader (Varian). Control assays were
performed in the same conditions without inhibitor peptides. All
assayswere done in triplicate and the results are expressed as themean
value±S.D. Ki was determined by nonlinear regression analysis
(Leatherbarrow, 1990) using the GraphPad Prism software (GraphPad,
2010).
2.4. Determination of IC50 for proteases using synthetic substrates
To determine the IC50 values of the inhibitor peptides against
proteases, 15 μl of proteases (HNE (20 μg/ml)), exudate (2.4 μg/ml)
and PPE (175 μg/ml) were incubated with 15 μl of peptide inhibitors
(20–80 μM) for 30 min at 25 °C. The volume was adjusted to 300 μl
with respective buffer solutions. The reaction was started after the
addition of 27 μl of 400 μMof N-Methoxysuccinyl-Ala-Ala-Pro-Val-p-
nitroanilide (HNE and exudate) and N-Succinyl-Ala-Ala-Ala-p-
nitroanilide (PPE). The increase in optical density at 410 nm was
monitored over 10 min using a microplate reader (Varian). All
assays were done in triplicate and the results are expressed as mean
value±S.D. IC50 was determined using the GraphPad Prism soft-
ware (GraphPad, 2010).
2.5. Determination of IC50 for HNE and exudate using insoluble elastin
The ability of the synthetic peptides to inhibit the hydrolysis of
insoluble elastin by HNE was determined spectrophotometrically
using elastin congo-red as a substrate according to the method
previously described (Naughton and Sanger, 1961). Brieﬂy, elastin
congo-red (2 mg/ml) and HNE (20 μg/ml) and exudate (2.4 μg/ml)
were incubated with various concentrations of peptides (20–80 μM)
in 1.5 ml of 0.1 M Tris–HCl buffer, pH 8.0 containing 0.2 M NaCl at
30 °C for 1 h. After incubation, the reaction was stopped by the
addition of 1.5 ml of 0.1 M acetic acid and, the mixture was
centrifuged at 1500 g for 10 min at room temperature. After
centrifugation, the absorbance of the supernatant was measured at
495 nm using a Heλios γ ThermoSpectronic spectrophotometer.
Triplicate measurements were made for each inhibitor concentration
and the results are expressed as mean value±S.D.
2.6. Silk ﬁbroin ﬁlms preparation and peptide incorporation
Silk ﬁbroin (ﬁbroin) ﬁlms were prepared as described before
(Vasconcelos et al., 2010). Brieﬂy, ﬁbroin solution 1% (w/v) was
prepared by dissolving degummed silk ﬁbers into a saturated solution
of LiBr at 60 °C for 3 h. The solution was then ﬁltered, and dialyzed
against distilled water using, cellulose tubing (molecular-weight cut-
off of 12000–14000 Da), until complete removal of salts.
The peptides (40 μM) were mixed with the ﬁbroin solution for
5 min at room temperature. After this time, solutions were cast in 24-
well plates and dried overnight at room temperature. In order to
induce the transition of ﬁbroin from random coil to β-sheet structure
Fig. 1. Three-dimensional structure of soybean trypsin/chymotrypsin Bowman–Birk
inhibitor in solution (PDB code 1BBI (Werner and Wemmer, 1992)). Loop I as shown is
red, loop I' is blue and the disulphide bond is yellow.
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and consequently insolubility, the ﬁlms were immersed in 90%(v/v)
methanol solution for 30 min and then washed in distilled water and
air dried. Films were incubated with HNE for 1 h at 25 °C and then
aliquots were taken for the evaluation of HNE activity decrease as
described above.
2.7. Cytotoxicity evaluation
The peptides were tested for cytotoxicity according to the ISO
standards (10993–5, 2009). The BJ5ta cell line (normal human skin
ﬁbroblasts) was maintained according to ATCC recommendations
(4 parts Dulbecco's Modiﬁed Eagle's Medium (DMEM) containing
4 mM L-glutamine, 4.5 g/l glucose, 1.5 g/l sodium bicarbonate, and 1
part of Medium 199, supplemented with 10% (v/v) of fetal
bovine serum (FBS), 1%(v/v) of Penicillin/Streptomycin solution
and 10 μg/ml hygromycin B). The cells were maintained at 37 °C in a
humidiﬁed atmosphere of 5% CO2. Culture medium was refreshed
every 2 to 3 days.
Cells were seeded at a density of 10×103cells/100 μl/well on 96-well
tissue culture polystyrene (TCPS) plates (TPP, Switzerland) the day
before experiments and then exposed to different peptide concentra-
tions added to fresh culture medium. At 24 and 48 h of exposure, cell
viability was determined using the MTS assay (CellTiter 96® Non-
Radioactive Cell Proliferation Assay, Promega, EUA).
MTS tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) is a col-
ored formazan substrate which is converted by several mitochondrial
and cytoplasmic enzymes in viable cells into a soluble, pink
ﬂuorescent product. 20 μl of MTS compound were added to each
well containing 100 μl of culture medium. After 4 h of incubation at
37 °C the absorbance at 490 nm was measured in a microplate reader
(Spectramax 340PC). The quantity of formazan formed is directly
proportional to the number of viable cells. Data are presented as
average±S.D. Non-parametric, Wilcoxon matched samples test was
used, with statistically signiﬁcant differences when Pb0.05. All
calculations were performed using GraphPad software (GraphPad,
2010).
3. Results
In this study synthetic peptides based on the anti-trypic loop of the
Bowman–Birk inhibitor protein were used for the design of new
inhibitor peptides. The peptide was selected from the combinatorial
library (Mcbride et al., 1999) of Bowman–Birk inhibitor-derived
peptides. To the selected peptide (WCTASVPPQCYG, Fig. 2, white
circles), modiﬁcationsweremade in theN-terminal, by the introduction
of methionine (M) and glycine (G) (Peptide 2, MGWCTASVPPQCYG,
Fig. 2, light gray circles). This sequence was maintained and a glycine/
alanine (GA) tail (n=7) was added to the C-terminal (Peptide 3,
MGWCTASVPPQCYG(GA)7, Fig. 2, dark gray circles).
3.1. Determination of activity loss over time
The time of incubation necessary to obtain a decrease in 50% of
elastase activity, was determined by incubating the peptides with PPE,
HNE and wound exudate and the decrease in activity was monitored
over the time as described in experimental section. In our study, it was
also used elastatinal, a low molecular weight elastase inhibitor, as a
control. Fig. 3, represents the activity loss obtained with the lowest
concentration of peptides used (20 μM) after 30 min of incubation. It
can be observed that after 30 min it was obtained more than 50% of
activity loss for all the peptides. Nevertheless, both peptide 3
(MGWCTASVPPQCYG(GA)7) and elastatinal present higher activity
loss than peptide 2 (MGWCTASVPPQCYG), especially for HNE,
indicating the higher inhibitory activity. The time of incubation
determined (30 min) will be used in the further experiments.
3.2. Inhibition kinetics
In order to establish the inhibition mechanism, PPE, HNE and
wound exudate were incubated with different peptide concentra-
tions. To analyse the inhibition, Lineweaver–Burk plots, i.e. double-
reciprocal plot for the hydrolysis of the synthetic substrates were
determined for all the peptides and enzyme (Data not show for PPE
and wound exudate). Fig. 4 represents the progress curves for the
inhibition of HNE by both peptides (Fig. 4A and B) and the
correspondent Lineweaver–Burk plot (Fig. 4C and D). From the
analysis of the last, it can be determined the mechanism of inhibition
and from the results , peptide MGWCTASVPPQCYG and
MGWCTASVPPQCYG(GA)7 are competitive inhibitors for HNE, PPE
and wound exudate. Then, non-linear regression was applied to
determine the Michaelis–Menten constant (Km) and Vmax by Eq. 1:
V = Vmax ×
S½ "
S½ " + Km
ð1Þ
V is the enzyme reaction velocity; Vmax is the maximum enzyme
reaction velocity which is attained when all the subsites of the enzyme
are occupied by the substrate; [S] is the substrate concentration and Km
is the Michaelis–Menten constant that represents the substrate
concentration when half of the binding sites are occupied. The results
also conﬁrmed the type of inhibition present because Vmax remains
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Fig. 2. Representation of the peptide sequences mimicking the reactive site loop of the Bowman–Birk inhibitor protein.
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unchanged in the presence of different peptide concentrations and,
there is an increase in the Km. These values are higher for HNE in the
presence of peptide MGWCTASVPPQCYG(GA)7, indicating that this
peptide causes higher inhibition. The competitive inhibition exhibited
for peptides MGWCTASVPPQCYG and MGWCTASVPPQCYG(GA)7 may
work through direct competition with the substrate by binding to the
active site, or binding to a remote site and causing a conformational
change in the enzyme.
Competitive inhibitors cause an apparent increases of Km (i.e., the
inhibitor interferes with substrate binding) without affecting Vmax
(inhibitor cannot bind to the complex enzyme-substrate). Therefore,
inhibition constants (Ki) were determined by themodiﬁedMichaelis–
Menten equation for competitive inhibition (Eq. (2)):
V = Vmax ×
S½ "
S½ " + Km 1 +
I½ "
Ki
! " ð2Þ
[I] is the inhibitor concentration and Ki (inhibition constant) is the
dissociation constant of the enzyme-inhibitor complex.
The inhibition constants (Ki) obtained for the peptides are
presented in Table 1. It can be observed that the inhibition constants
obtained for peptide MGWCTASVPPQCYG(GA)7 presents the best
results, especially for HNE. There is an improvement in Ki for HNE
obtained for peptide WCTASVPPQCYG (McBride et al., 2002), when
amino acid residues were added to both N- and C-terminals.
The Ki ratio presented shows the selectivity of the peptides for
HNE. The results indicate that peptide MGWCTASVPPQCYG(GA)7
presents higher speciﬁcity for HNE. Moreover, Ki values obtained for
PPE, HNE and wound exudate with the peptides are comparable, and
in some cases better (MGWCTASVPPQCYG(GA)7 for HNE), with the Ki
obtained for elastatinal. A very important result and approach of this
study, is the use of a human wound exudate. The peptides
MGWCTASVPPQCYG and MGWCTASVPPQCYG(GA)7 present good
inhibition constants and the differences obtained when compared
with HNE (Sigma) might be related with the presence of other
proteases present in the exudate that can interferewith the inhibition.
The hydrolytic stability of Bowman–Birk inhibitor peptides used in
this study was determined by mass spectrometry analysis (Data not
shown). The hydrolysis of the peptides occurred after 6 h of
incubation with the studied enzymes.
Fig. 3. Activity loss obtained after 30 min of incubation at 25 °C of elastases with
20 μM of peptides 2, 3 or elastatinal. (Peptide 2=MGWCTASVPPQCYG, peptide
3=MGWCTASVPPQCYG(GA)7).
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Fig. 4. Progress curves for the inhibition of HNE by peptide 2 (A) and peptide 3 (B) for the hydrolysis of the synthetic substrate. The correspondent Lineweaver–Burk plots are
represented in (C) peptide 2 and (D) peptide 3. (Peptide 2=MGWCTASVPPQCYG, peptide 3=MGWCTASVPPQCYG(GA)7).
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3.3. Determination of IC50 for proteases
IC50 is deﬁned as the concentration of inhibitor necessary to cause
the decrease of 50% in HNE activity and is determined by Eq. 3 (Cheng
and Prusoff, 1973):
IC50 = Ki × 1 +
S½ "
Km
# $
ð3Þ
The inhibitory activity of peptides MGWCTASVPPQCYG and
MGWCTASVPPQCYG(GA)7 against PPE, HNE and wound exudate
were evaluated using synthetic and natural substrates. The results
were compared with the activity of elastatinal inhibitor as control.
IC50 values obtained for peptides MGWCTASVPPQCYG,
MGWCTASVPPQCYG(GA)7 and elastatinal, using synthetic substrates,
are presented in Table 2 and are within the range of 11–19 μM. Once
again peptide MGWCTASVPPQCYG(GA)7 shows the lowest IC50 value
which is the result of a higher inhibitory activity already demonstrat-
ed by the Ki values. The ability of peptides MGWCTASVPPQCYG and
MGWCTASVPPQCYG(GA)7 to inhibit the hydrolysis of insoluble
elastin by HNE was also evaluated. Peptides MGWCTASVPPQCYG
and MGWCTASVPPQCYG(GA)7 present lower IC50 values in compar-
ison with elastatinal under our assay conditions. Peptide
MGWCTASVPPQCYG(GA)7 presents higher inhibitory activity in the
presence of a natural substrate.
3.4. Determination of peptides inhibitory activity after incorporation into
silk ﬁbroin ﬁlms
The differences in inhibitory activity between peptide
MGWCTASVPPQCYG and MGWCTASVPPQCYG(GA)7 might be related
with the GA tail introduced in the C-terminal of peptide
MGWCTASVPPQCYG(GA)7. To test this hypothesis, peptides were
incorporated in ﬁbroin ﬁlms prepared as described in the experimen-
tal section and, the decrease in activity was monitored after 1 h of
incubation of ﬁbroin ﬁlms, containing peptide MGWCTASVPPQCYG,
MGWCTASVPPQCYG(GA)7 and elastatinal, with HNE. Fibroin ﬁlm
without peptides was used as control. It can be seen from Fig. 5 that
the activity loss obtained for peptide MGWCTASVPPQCYG and
MGWCTASVPPQCYG(GA)7 is similar. The GA tail has a high afﬁnity
towards ﬁbroin thus, after incorporation and ﬁlm crystallization, this
tail is no longer available to interact with the enzyme. This result
indicates that the GA tail plays an important role in the inhibition of
HNE.
3.5. Molecular-docking analysis
Molecular-docking analysis was done in order to better
understand the mechanism of HNE inhibition by the new peptides.
Docking calculations were made using AutoDock Vina version 1.1.1
(Trott and Olson, 2010). For the calculations we use the X-ray
structure, PDB code 1B0F (Cregge et al., 1998), after removing the
ligand present in this structure. This structure was used as the
receptor without ﬂexible side chains. The ligands were made
ﬂexible turning all possible bonds rotatable. Cyclic and amide
bonds were considered as non-rotatable. Considering these we
get 37 torsions for peptide 1, 44 torsions for peptide 2 and 72
torsions for peptide 3. For peptides 1 (WCTASVPPQCYG) and 2
(MGWCTASVPPQCYG) the grid size was chosen in order to included
not only the known catalytic site of HNE but also the all the
surrounding area. The surface in the opposite side of the enzymewas
not considered. For the peptide 3 (MGWCTASVPPQCYG(GA)7), and
because this peptide is bigger, the grid was centered at the center of
the protein and big enough to include all the protein and peptide 3
interacting with any spot of the surface. This procedure allows us to
obtain the most favorable conﬁguration representing the inter-
action between peptide 3 and HNE, without any kind of external
impositions.
3.6. Cytotoxicity evaluation
The biocompatibility of the designed peptides was assessed
through the use of ﬁbroblast cultures. A preliminary screening was
made usingmurine embryonic ﬁbroblasts cells (MEFs) as ameasure of
global cytotoxicity. In this study, a wide range of peptide concentra-
tions (from 20 to 80 μM) used for inhibition assays was evaluated and
no toxicity was observed (Data not shown). The results obtained with
MEFs were then conﬁrmed with human skin ﬁbroblasts, testing the
lowest and highest peptide concentrations previously used and no
additional damage to the cells was detected in any case. Fig. 7 shows
the cell viability of human skin ﬁbroblasts after 24 h (a) and 48 h (b)
of incubation with the various peptides. In all cases, the cell viability
was close to 100% indicating that peptides MGWCTASVPPQCYG and
MGWCTASVPPQCYG(GA)7 can be safely applied to the skin at these
concentrations.
Table 1
Inhibition constants (Ki) obtained for the peptides against PPE, HNE and wound
exudate. Peptide 1=WCTASVPPQCYG, peptide 2=MGWCTASVPPQCYG, peptide
3=MGWCTASVPPQCYG(GA)7).
Peptide Ki (μM) KiPPE/KiHNE
PPE HNE Exudate
Peptide 1⁎ 13 2.77 – –
Peptide 2 8.1±1.6 6.3±1.2 7.0±1.8 1.3
Peptide 3 7.0±2.0 0.4±0.01 3.1±0.9 17.5
Elastatinal 9.7±1.4 6.7±1.1 7.8±1.2 1.2
⁎ Values were obtained from the literature (McBride et al., 2002).
Table 2
Inhibitory activity of peptide and elastatinal against PPE, HNE andwound exudate using
synthetic and natural substrates. (Peptide 2=MGWCTASVPPQCYG, peptide
3=MGWCTASVPPQCYG(GA)7).
Enzyme IC50 (μM)
Peptide 2 Peptide 3 Elastatinal
PPE 18.7±0.06 16.0±0.06 13.8±0.06
HNE 19.2±0.07 11.5±0.06 12.2±0.05
Exudate 16.0±0.09 13.1±0.06 14.3±0.07
HNE (insoluble elastin) 29.3±0.1 25.3±0.1 37.6±0.09
Exudate (insoluble elastin) 31.8±0.04 26.9±0.05 41.9±0.04
Fig. 5. Activity loss of HNE after 1 h of incubation at 25 °C with SF ﬁlms incor-
porating peptide 2, 3 and elastatinal. (Peptide 2=MGWCTASVPPQCYG, Peptide
3=MGWCTASVPPQCYG(GA)7).
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4. Discussion
Accordingly to the nomenclature of Schechter and Berger
(Schechter and Berger, 1967), the primary contact region between
the inhibitor and the enzyme is the scissile peptide bond P1–P1′.
Therefore, the speciﬁcity of the inhibition is dictated by the P1 residue
which typically reﬂects the substrate preference of the target enzyme
(Lu et al., 1997; Qasim et al., 1997). The peptide selected from the
combinatorial library (Mcbride et al., 1999) has an alanine residue in
the P1 position (Fig. 2). This residue in this position is consistent with
the substrate speciﬁcity of elastase for small alkyl side chains (Harper
et al., 1984; McRae et al., 1980; Stein et al., 1985). The stability and
consequently the biological activity of the Bowman–Birk inhibitor-
based peptides are supported by an extensive intramolecular
hydrogen-bond network. The main-chain to main-chain hydrogen
bond between P2 and P1′ (Fig. 2, dash lines) is responsible for
projecting the P1 side-chain outwards for the primary interaction
with the enzyme (Lin et al., 1993; Voss et al., 1996). The cis-Pro-trans-
Pro motif in the P3′-P4′ positions and, the disulphide bridge
covalently linking the P3–P6′ positions together with the hydrogen
bond network guarantees the β-hairpin conformation typical of the
Bowman–Birk inhibitor protein (Brauer et al., 2001; Mcbride et al.,
1999; McBride et al., 2002). In this study, to this 9-residue motif,
modiﬁcations were made in the N-terminal, by the introduction
of methionine (M) and glycine (G) (Peptide 2, MGWCTASVPPQCYG,
Fig. 2, light gray circles). This sequence was maintained and a
glycine/alanine (GA) tail (n=7) was added to the C-terminal
(Peptide 3, MGWCTASVPPQCYG(GA)7, Fig. 2, dark gray circles).
The primary objective of adding this GA tail was to increase the
afﬁnity of this peptide to silkﬁbroin-basedmaterials. In thisway,ﬁbroin-
based wound dressings will be easily obtained with a speciﬁc biological
activity: elastase inhibition (Vasconcelos et al., 2010). Nevertheless the
results presented indicated that this GA tail has a very important role in
the HNE inhibition. Peptide MGWCTASVPPQCYG(GA)7, presented Ki
and IC50 values for human elastase of 0.4 μM and 11.5 μM respec-
tively. The Ki was 7-fold lower when compared with the peptide
WCTASVPPQCYG (McBride et al., 2002) indicating a higher inhib-
itory activity. In contrast, the modiﬁcations introduced only at the
N-terminal (peptide MGWCTASVPPQCYG) show a slightly improve-
ment in the inhibition of PPE, but a worst result for the inhibition
HNE when compared with peptide WCTASVPPQCYG. The better
results obtained with peptide MGWCTASVPPQCYG(GA)7 might be
related to the increase in hydrophobicity resulting from the GA
tail which corresponds to the preference of HNE for hydrophobic
substrates. Although not possible, from the activity measurements,
to quantify the exact number of binding sites, one might speculate
that the potent binding between peptide MGWCTASVPPQCYG(GA)7
and HNE might be due to the binding of this GA tail to the active
center or adjacent active sites of HNE.
The amino acid composition of silk ﬁbroin consists primarily of
glycine, alanine and serine amino acids which form typical – (−ala-
gly-)n – repeating motifs (Zhou et al., 2000). In the ﬁber, ﬁbroin
chains are aligned along the ﬁber axis held together by a close
network of interchain hydrogen bondswith adjacent – (−ala-gly-)n –
sequences forming the well known β-sheets crystals (Arai et al., 2001;
Inoue et al., 2000). Therefore, peptide MGWCTASVPPQCYG(GA)7 will
P1
P1
P’1 P’1
P1
P’1
A B C
Fig. 6. Docking images of the interactions between HNE and peptides 1(A), 2(B) and 3(C). The catalytic triad is shown in red. (Peptide 2=MGWCTASVPPQCYG, Peptide
3=MGWCTASVPPQCYG(GA)7).
Fig. 7. Viability of human normal skin ﬁbroblasts after 24 h (left panel) and 48 h (right panel) of contact with peptides 2, 3 and elastatinal. Only the positive control (treatment with
Triton detergent) revealed diminished cell viability. (* = signiﬁcantly different from all the other tested conditions, Pb0.05). (Peptide 2=MGWCTASVPPQCYG, Peptide
3=MGWCTASVPPQCYG(GA)7).
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have a high afﬁnity towards ﬁbroin ﬁlms due to the GA tail. The
activity loss of HNE obtained in the presence of ﬁbroin ﬁlms
incorporating peptides indicated that the inhibitory activity of peptide
MGWCTASVPPQCYG(GA)7 decreases. The activity loss obtained was
similar to the one obtained for peptide 2 (MGWCTASVPPQCYG)which
is a less potent inhibitor already demonstrated by inhibition kinetics
results. This fact clearly demonstrates the importance of GA tail on the
inhibitory activity. The loss in activity veriﬁed for peptide
MGWCTASVPPQCYG(GA)7 is explained by the fact that after ﬁlm
crystallization a transition from random coil to β-sheet of ﬁbroin ﬁlms
occurs and the GA tail of this peptide may thus become a part of these
β-sheet crystals being unavailable for the inhibitory activity.
Docking analysis indicated that the reactive site-loop of the
Bowman–Birk inhibitor-peptides occupied most of the active site,
inhibiting the HNE activity as already demonstrated by others
(Mcbride et al., 1999; Nishino et al., 1977; Odani and Ikenaka, 1973;
Terada et al., 1978). This also conﬁrms the competitive inhibition
obtained for Bowman–Birk inhibitor-peptides that was conﬁrmed by
our kinetic analysis. Nevertheless, modiﬁcations made on the C- and
N-terminal of peptides had inﬂuence on the binding mode to the
active site of HNE.
Peptide MGWCTASVPPQCYG had two more residues (MG) at the
N-terminal, which increases the hydrophobic interactions between P
and P′ side-chains (methionine is hydrophobic) thereby closing the
loop (Fig. 6B) when compared to peptide WCTASVPPQCYG (Fig. 6A).
This might increase the distance of P1 (Ala) to the active centre
decreasing the inhibition. On the other hand, the increase in
hydrophobicity of peptide MGWCTASVPPQCYG(GA)7, given by the
GA tail at the C-terminal causes the opening of the loop (Fig. 6C). This
peptide showed the best HNE inhibitory activity. Docking analysis
suggested that the primary interaction with the active site is also
made by the P1, as observed for the other two peptides. Nevertheless
the interaction of peptideMGWCTASVPPQCYG(GA)7with the enzyme
tends to be more favorable. The hydrophobic GA tail has the ability to
interact with the remaining enzyme, leading to a stronger interaction
between the two species (Fig. 6C). This is consistent with what others
observed for this particular enzyme. It was shown that HNE activity
increases with the length of the synthetic substrates indicating that
HNE has an extended binding site (Bode et al., 1986; Lestienne and
Bieth, 1980). It is possible, as shown by docking analysis, that HNE
accommodates the GA tail due to the high length and hydrophobicity
leading to stronger interactions and, therefore, to higher inhibition
rates.
Conclusion
The results presented in this study conﬁrmed the ability of
Bowman–Birk inhibitor peptides to inhibit human neutrophil elastase
(HNE). Peptide MGWCTASVPPQCYG and MGWCTASVPPQCYG(GA)7
are competitive inhibitors of HNE being peptide MGWCTASVPPQCYG
(GA)7 the one that presents higher inhibitory activity. This is due to
the presence of the GA tail that increases hydrophobicity. Conse-
quently, the afﬁnity for HNE increases because of the preference of
this enzyme for hydrophobic residues. The importance of the GA tail
in the inhibition HNE was conﬁrmed by incorporating peptides in a
silk ﬁbroin matrix and by molecular-docking analysis. After incorpo-
ration and subsequent crystallization of ﬁbroin ﬁlms, the inhibitory
activity was similar to that obtained for peptide MGWCTASVPPQCYG.
This happens because the GA tail, upon crystallization, is no longer
available for the inhibition.
Peptide MGWCTASVPPQCYG and MGWCTASVPPQCYG(GA)7 were
also able to inhibit HNE present on a chronic wound exudate. This fact,
along with the cytocompatibility observed with human skin ﬁbro-
blasts, indicates that these peptides, especially peptide
MGWCTASVPPQCYG(GA)7, are potential bioactive agents against
deleterious HNE-derived inﬂammatory episodes such as chronic
wounds.
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